Cargando…

Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer

BACKGROUND: Although the patients with muscle-invasive bladder cancer (MIBC) generally have poor prognosis, the utility of these biomarkers for the prediction of oncological outcomes in MIBC has not been completely explored. Ghrelin regulates processes associated with cancer, including cell prolifer...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomioka, Masayuki, Yoneyama, Tohru, Tobisawa, Yuki, Kawase, Kota, Nakai, Chie, Takai, Manabu, Kato, Daiki, Iinuma, Koji, Nakane, Keita, Mizutani, Kosuke, Hashimoto, Yasuhiro, Koie, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039575/
https://www.ncbi.nlm.nih.gov/pubmed/33850754
http://dx.doi.org/10.21037/tau-20-1489
_version_ 1783677622166749184
author Tomioka, Masayuki
Yoneyama, Tohru
Tobisawa, Yuki
Kawase, Kota
Nakai, Chie
Takai, Manabu
Kato, Daiki
Iinuma, Koji
Nakane, Keita
Mizutani, Kosuke
Hashimoto, Yasuhiro
Koie, Takuya
author_facet Tomioka, Masayuki
Yoneyama, Tohru
Tobisawa, Yuki
Kawase, Kota
Nakai, Chie
Takai, Manabu
Kato, Daiki
Iinuma, Koji
Nakane, Keita
Mizutani, Kosuke
Hashimoto, Yasuhiro
Koie, Takuya
author_sort Tomioka, Masayuki
collection PubMed
description BACKGROUND: Although the patients with muscle-invasive bladder cancer (MIBC) generally have poor prognosis, the utility of these biomarkers for the prediction of oncological outcomes in MIBC has not been completely explored. Ghrelin regulates processes associated with cancer, including cell proliferation, apoptosis, cell migration, cell invasion, and angiogenesis. Thus, we aimed to evaluate the impact of serum ghrelin levels on survival in MIBC. METHODS: In this study, we reviewed the clinical and pathological records of 56 patients who were diagnosed with MIBC between November 2015 and November 2019 at Gifu and Hirosaki University Hospitals. We focused on 27 patients who had received chemotherapy and collected blood samples before and after chemotherapy. Blood samples were collected before chemotherapy and after completing two cycles of chemotherapy. Serum acyl (AG) and desacyl ghrelin (DG) were measured using AG and DG enzyme-linked immunosorbent assay kits (SCETI, Tokyo, Japan), respectively. RESULTS: The 3-year overall and progression-free survival (PFS) rates were 82.9% and 68.3%, respectively. According to the AG level after chemotherapy, the 3-year PFS rates were 77.5% and 53.0% in patients with AG levels ≥1.34 and <1.34 pg/mL, respectively (P=0.038). With regard to DG levels after chemotherapy, the 3-year PFS rates were 90.9% and 43.3% in patients with DG levels <92.3 and ≥92.3 pg/mL, respectively (P=0.039). On multivariate analysis, serum AG levels were significantly associated with PFS. CONCLUSIONS: This study suggested the usefulness of the ghrelin as a prognostic predictor of PFS in patients with MIBC.
format Online
Article
Text
id pubmed-8039575
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-80395752021-04-12 Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer Tomioka, Masayuki Yoneyama, Tohru Tobisawa, Yuki Kawase, Kota Nakai, Chie Takai, Manabu Kato, Daiki Iinuma, Koji Nakane, Keita Mizutani, Kosuke Hashimoto, Yasuhiro Koie, Takuya Transl Androl Urol Original Article BACKGROUND: Although the patients with muscle-invasive bladder cancer (MIBC) generally have poor prognosis, the utility of these biomarkers for the prediction of oncological outcomes in MIBC has not been completely explored. Ghrelin regulates processes associated with cancer, including cell proliferation, apoptosis, cell migration, cell invasion, and angiogenesis. Thus, we aimed to evaluate the impact of serum ghrelin levels on survival in MIBC. METHODS: In this study, we reviewed the clinical and pathological records of 56 patients who were diagnosed with MIBC between November 2015 and November 2019 at Gifu and Hirosaki University Hospitals. We focused on 27 patients who had received chemotherapy and collected blood samples before and after chemotherapy. Blood samples were collected before chemotherapy and after completing two cycles of chemotherapy. Serum acyl (AG) and desacyl ghrelin (DG) were measured using AG and DG enzyme-linked immunosorbent assay kits (SCETI, Tokyo, Japan), respectively. RESULTS: The 3-year overall and progression-free survival (PFS) rates were 82.9% and 68.3%, respectively. According to the AG level after chemotherapy, the 3-year PFS rates were 77.5% and 53.0% in patients with AG levels ≥1.34 and <1.34 pg/mL, respectively (P=0.038). With regard to DG levels after chemotherapy, the 3-year PFS rates were 90.9% and 43.3% in patients with DG levels <92.3 and ≥92.3 pg/mL, respectively (P=0.039). On multivariate analysis, serum AG levels were significantly associated with PFS. CONCLUSIONS: This study suggested the usefulness of the ghrelin as a prognostic predictor of PFS in patients with MIBC. AME Publishing Company 2021-03 /pmc/articles/PMC8039575/ /pubmed/33850754 http://dx.doi.org/10.21037/tau-20-1489 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Tomioka, Masayuki
Yoneyama, Tohru
Tobisawa, Yuki
Kawase, Kota
Nakai, Chie
Takai, Manabu
Kato, Daiki
Iinuma, Koji
Nakane, Keita
Mizutani, Kosuke
Hashimoto, Yasuhiro
Koie, Takuya
Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer
title Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer
title_full Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer
title_fullStr Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer
title_full_unstemmed Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer
title_short Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer
title_sort ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039575/
https://www.ncbi.nlm.nih.gov/pubmed/33850754
http://dx.doi.org/10.21037/tau-20-1489
work_keys_str_mv AT tomiokamasayuki ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer
AT yoneyamatohru ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer
AT tobisawayuki ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer
AT kawasekota ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer
AT nakaichie ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer
AT takaimanabu ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer
AT katodaiki ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer
AT iinumakoji ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer
AT nakanekeita ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer
AT mizutanikosuke ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer
AT hashimotoyasuhiro ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer
AT koietakuya ghrelinafterchemotherapyasaprognosticpredictorofprogressionfreesurvivalinpatientswithmuscleinvasivebladdercancer